Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Investor Presentation (February 2022)
10 slides from Jagsonpal Pharmaceuticals's investor presentation, Feb 22, 2022
Slide 1: Exchange filing cover letter: Investor Presentation
JAGSONPAL PHARMACEUTICALS LIMITED Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900 Email: cs@jagsonpal.com; nandita.singh@jagsonpal.com CIN No. L74899DL1978PLC009181 Date: February 21, 2022 To, To, The Department of Cor
Slide 2: Jagsonpal Pharmaceuticals Limited Corporate Presentation
Jagsonpal Pharmaceuticals Limited Corporate Presentation February 2022
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Jagsonpal Pharmaceuticals at a Glance
Jagsonpal Pharmaceuticals at a Glance FY21 Revenue from 70%+ Founded in 1964, track Operations(1): INR 188cr. Focus on Gynaec and record of ~47 years FY21 EBITDA(1): INR19cr. Orthopedic Therapy FY21 PAT: INR17cr. Segments(2) 5+ Brands Field force of 600+ among top 10 brands with personnel #1/#2 Mark
Slide 5: Divisional Overview
Divisional Overview Revenue contribution within Division Brief Overview Key brands formulations business (FY21)(1) Maintaine ◼ Houses major brands across various Pharma ◼ Indocap specialties such as gynecology, ortho 88% Division ◼ Lycored and anti-biotics among others ◼ Metadec Dedicated gynecology
Slide 6: Overview of Gynecology Portfolio
Overview of Gynecology Portfolio Overview ◼ Product portfolio with indications including female infertility, pregnancy supervision, uterine FY21 Revenue Contribution(2) dysfunction, irregular menstruation ◼ In addition to the key brands below, Company has recently launched two Dydrogesterone formula
Slide 7: Overview of Orthopedic Portfolio
Overview of Orthopedic Portfolio Overview FY21 Revenue Contribution(2) ◼ Product portfolio with indications including osteoarthritis, arthritis, rheumatoid 29% arthritis and gout Key Brands Brands Indocap Metadec COLLA-2 (New Launch) Arthritis, Back Pain, Gout, Ankylosing Indication Osteoporosis, Fr
Slide 8: Financial Performance
Financial Performance % YoY % YoY INR Cr. (FYE March) FY20 FY21 9MFY21 9MFY22 Growth Growth Revenue from 159 188 19% 145 174 20% Operations(1) EBITDA(1) 9 19 123% 14 25 80% % Margin 5% 10% 10% 14% PAT 8 17 116% 12 20 64% % Margin 5% 9% 8% 11% Footnote: (1) Excludes other income 7
Slide 9: Potential Levers for Future Growth and Operational Improvement Initiatives
Potential Levers for Future Growth and Operational Improvement Initiatives ◼ Management has identified potential growth levers and operational improvement initiatives. The implementation of the growth levers and initiatives could contribute to high-teens revenue growth over the next 5 years (1) and
Slide 10: Thank you
Thank you
Jagsonpal Pharmaceuticals — Investor Presentation (February 2022) on 6ix